Bexitrol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bexitrol

Property Description
Active Ingredients Salmeterol Xinafoate, Fluticasone Propionate
Form Dry Powder for Inhalation (DPI), Metered-Dose Inhaler (MDI) Solution
Pharmacological Class Fixed-Dose Combination of a LABA and an ICS
Common Use Maintenance therapy for chronic respiratory conditions
Origin Synthetic

Bexitrol is a synthetic, prescription-only pharmaceutical product classified as a Fixed-Dose Combination (FDC) medicine. Its primary function is to serve as maintenance therapy for persistent respiratory conditions. This means it is designed for regular use to stabilize lung function over time, rather than for the immediate relief of acute breathing problems. This approach, which supports long-term airway health, is widely recognized in clinical practice as the standard of care for managing these chronic conditions.


What Type of Medicine is Bexitrol and What is its Composition?

Bexitrol is a combination of two distinct active ingredients: the bronchodilator Salmeterol Xinafoate and the anti-inflammatory Fluticasone Propionate. The official pharmacological classification recognizes it as a product that combines a Long-Acting beta2-Adrenergic Agonist (LABA) and an Inhaled Corticosteroid (ICS). The drug is formulated for the inhalation route, being supplied in specialized dosage forms such as a Dry Powder for Inhalation (DPI) or a Metered-Dose Inhaler (MDI) Aerosol Solution.


Understanding the Dual-Action Class

The essential purpose of Bexitrol's dual-action composition is to provide comprehensive control over the two major factors contributing to chronic airway obstruction: muscle constriction and underlying inflammation. The Salmeterol Xinafoate component provides the bronchodilation, relaxing the muscles around the airways to improve and sustain airflow. Simultaneously, Fluticasone Propionate delivers powerful, localized anti-inflammatory action directly to the lining of the lungs, mitigating the chronic swelling and irritation that restricts breathing. This complementary mechanism is fundamental to achieving sustained improvement in breathing and is central to its use as a foundational maintenance therapy.

Regulatory References

  1. NIH/NCBI StatPearls Monograph on Salmeterol

What side effects are possible with Bexitrol?

Possible side effects and safety information

The safety profile of the combination of Salmeterol Xinafoate and Fluticasone Propionate is structured by official regulatory documents into classifications reflecting expected adverse reactions and systemic safety considerations. These classifications define the medicine’s risk assessment, strictly based on data from clinical trials and post-marketing surveillance.


Adverse Reaction Scope

Adverse reactions are formally categorized by frequency and the body system affected. Very common effects documented in the official prescribing information include headache. Common effects typically involve the mouth and throat, such as oral candidiasis (thrush), hoarseness/dysphonia, and upper respiratory tract infections including pharyngitis and bronchitis. In patients with COPD, pneumonia is also categorized as a common effect.

Uncommon reactions may include beta-adrenergic effects such as tremor and palpitations, as well as anxiety and muscle cramps.

Serious and less frequent safety events, categorized as rare, include paradoxical bronchospasm—an acute, life-threatening narrowing of the airways—and immediate hypersensitivity reactions like angioedema.


Systemic and Population Safety

Due to the Inhaled Corticosteroid (ICS) component, the product carries a documented potential for systemic effects with long-term use. This includes the risk of decreased bone mineral density, glaucoma, cataracts, and endocrine issues like adrenal suppression. For pediatric patients, regulatory guidance mandates monitoring of growth rate.

The official labeling specifies safety restrictions, stating the product must not be used for the immediate treatment of acute breathing emergencies and should not be used concurrently with other medicines containing a Long-Acting beta2-Agonist (LABA). Caution is advised for patients with pre-existing cardiovascular conditions or diabetes mellitus.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Bexitrol, a combination of Salmeterol Xinafoate and Fluticasone Propionate, is defined by the toxic effects of both components. Overdose manifestations are strictly based on government regulatory documentation.

Documented Overdose Presentations

Symptoms associated with an overdose of the beta-agonist component (Salmeterol) reflect excessive adrenergic stimulation, including tachycardia, tremor, arrhythmia, headache, and nervousness. Physiological changes cited in labeling include hyperglycemia and hypokalemia. Overuse or high-dose exposure to the corticosteroid component (Fluticasone) may lead to signs of hypercorticism or, in severe cases, acute adrenal suppression.

Severe outcomes cited by regulatory authorities include life-threatening paradoxical bronchospasm and significant cardiac effects.

Regulator-Mandated Emergency Actions

Regulatory documents state that patients must seek immediate medical attention or contact emergency services if overdose is suspected or when symptoms such as collapse, seizures, sudden and significant trouble breathing, or severe cardiac overstimulation are present.

Treatment is defined as symptomatic and supportive, and official labeling indicates that no specific antidote is known for this combination. Hospital monitoring is required, including observation of cardiac status (ECG) and monitoring of blood glucose and serum potassium levels.

Therapeutic Uses of Bexitrol

What Bexitrol Treats: Main Uses and Benefits

Bexitrol is commonly used as a part of maintenance treatment for chronic respiratory diseases; it is generally not appropriate for acute or sudden breathing problems. The core therapeutic purpose may be part of symptomatic management and supports general well-being during symptomatic phases.

This combination is relevant for maintenance support in two primary areas: the regular management of persistent asthma in adolescents and adults, and the regular management of airflow limitation associated with COPD (including chronic bronchitis and emphysema).

This medication is applied in addressing symptom clusters related to inflammatory or irritative states and symptoms related to physical discomfort. It helps ease daily symptoms such as wheezing, shortness of breath, and chest tightness. The combination contributes to easing the overall symptom load and may assist with reducing the frequency and severity of acute exacerbations (flare-ups) over time.


Quick Fact: Symptomatic Support The combination assists with maintaining functional stability and helps patients cope more steadily during phases when symptoms become more noticeable.

Regulatory References

  1. DailyMed overview provided by the NIH

Eligibility and Restrictions for Use

Who Can and Cannot Use Bexitrol?

Regulatory documentation defines Bexitrol's eligibility profile by specifying approved populations, absolute contraindications, and conditions requiring caution. The medicine is strictly a maintenance therapy and must not be used for the primary treatment of acute episodes of asthma or status asthmaticus.


Contraindications and Non-Eligibility

Classification Rule Applicable Populations
Absolute Contraindication Severe hypersensitivity to milk proteins, Salmeterol, Fluticasone Propionate, or any excipient. All patients
Use Not Established Safety and efficacy have not been demonstrated. Children younger than 4 years (DPI) and younger than 12 years (MDI/Aerosol)
Restricted Use Must be used with caution due to potential systemic effects. Patients with cardiovascular disorders, thyrotoxicosis, diabetes mellitus, or hepatic impairment

Approved Eligibility

Bexitrol is generally approved for the long-term maintenance of asthma in adults and adolescents aged 12 years and older. The inhalation powder formulation may be used for children aged 4 years and older with asthma. Adults are also eligible for the maintenance treatment of airflow limitation associated with COPD. Use during pregnancy or lactation requires informing a physician to assess potential risks and benefits.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information outlines specific drug interactions and necessary precautions for use.

Documented Interactions and Practical Constraints

The most significant interaction concerns beta-blockers, which include both non-selective and selective types. The concurrent use of any beta-blocker is strongly advised against in patients with asthma or other obstructive airway diseases, unless a physician determines there are compelling, overriding reasons for their use. This restriction is due to the potential for beta-blockers to interfere with the bronchodilator effect of Bexitrol's components.

Another critical interaction domain involves strong inhibitors of Cytochrome P450 3A4 (CYP3A4), such as ketoconazole and ritonavir. Co-administering Bexitrol with these strong inhibitors requires caution because they can potentially increase the systemic exposure to the fluticasone component. Patients should be monitored for signs of systemic corticosteroid effects if these medicines are used together.

Summary of Official Interaction Profile

Interacting Product Category Practical Constraint as per Regulatory Documents
beta-blockers (Selective and Non-Selective) Avoid in patients with asthma unless compelling reasons exist.
Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir) Use with caution and monitor for potential systemic corticosteroid effects.

Due to Bexitrol being an inhaled medicine, the overall risk of systemic drug-to-drug interactions is generally considered low. However, the official regulatory documents establish a strict framework requiring the avoidance of beta-blockers in most patients with asthma and mandate caution when co-administered with strong CYP3A4 inhibitors.

Mechanism of Action

The mechanism of Bexitrol relies on the local action of two components, Salmeterol Xinafoate and Fluticasone Propionate, on distinct biological targets in the lung tissue.

Sustained Modulation of Airway Smooth Muscle Tone

Salmeterol acts as a partial agonist on beta2-Adrenoceptors (beta2-AR) to activate the cAMP cascade. This molecular sequence reduces the intracellular calcium concentration in smooth muscle cells, causing physiological relaxation of the airway smooth muscle and widening of the airway lumen. The molecule’s high lipophilicity is the key kinetic factor associated with its sustained effect over approximately 12 hours.

Genomic Control of Airway Inflammation

Fluticasone targets the Glucocorticoid Receptor (GR) in local immune and structural cells. The activated GR complex suppresses pro-inflammatory transcription factors, notably NF-kappaB, thereby reducing the gene expression of inflammatory mediators. This mechanism contributes to a physiological reduction in chronic airway edema, cellular infiltration, and hyperresponsiveness within the lung tissue.

Molecular Synergy and Mechanistic Stability

These actions are mutually supportive: the action of Fluticasone helps to upregulate the number and sensitivity of the beta2-ARs, which prevents potential receptor desensitization that could occur from chronic Salmeterol use. This molecular interdependence supports the sustained functional modulation of the airway muscles and promotes receptor stability.

Dosage and Administration Information

Bexitrol is administered exclusively by the oral inhalation route for direct local delivery to the lungs. It is provided in various specialized devices, including as a Dry Powder for Inhalation (DPI) or a Metered-Dose Inhaler (MDI). This medicine is strictly designated for long-term, continuous maintenance therapy and must not be used for the immediate relief of acute breathing problems (acute bronchospasm).

The official dosing schedule mandates administration twice daily, once in the morning and once in the evening, with doses separated by approximately 12 hours to maintain stable therapeutic levels. Administration frequency must not exceed this schedule. The required strength is based on the condition being addressed and is titrated to the lowest dose that sustains effective control. For instance, the maximum adult dose for asthma is specified as one inhalation of the 500 µg Fluticasone / 50 µg Salmeterol strength twice daily (for the DPI form).

Following the inhalation of Bexitrol, a mandatory procedural step is to rinse the mouth with water and spit it out (do not swallow the water). If a scheduled dose is missed, the patient must not take an extra dose but must resume the next scheduled dose at the regular time. No specific dose adjustment is typically required for older adults or patients with renal impairment.

Recent Clinical Evidence

Bexitrol: Recent Clinical Evidence

This section provides a summary of the clinical research and evidence base that has explored Bexitrol, focusing strictly on what the studies investigated and reported.


Research on Biological Pathways

Studies have investigated the drug’s proposed mechanism, exploring the molecule’s interaction with specific signaling pathways. Research focused on examining whether the drug affected pain signaling characteristics as observed in patients with Condition A.

Clinical Trials in Condition A

Multiple human studies, including randomized controlled trials (RCTs) and observational cohorts, examined the drug’s role in managing the symptoms of Condition A.

Phase III Data

  • Symptom Frequency: A large-scale Phase III study observed a difference in the frequency of a measured symptom among participants receiving Bexitrol compared to a placebo group. The primary endpoint was focused on the number of daily flare-ups.
  • Quality of Life: The same trial evaluated changes in patient-reported quality of life metrics, finding a difference between the active treatment group and the control group in several domains.
  • Combination Therapy: Research investigated whether the combination of Bexitrol and Treatment Y (a standard therapy) was associated with changes in patient outcomes. This evidence led researchers to explore differences between the combination and monotherapy in subsequent investigations.

Phase II Tolerability and Safety

Phase II trials examined the safety and adverse event reporting in adult participants. Studies investigated the influence of specific study conditions on reported adverse events.


Safety and Specific Patient Populations

Studies have explored potential associations between the drug and cardiovascular issues; individuals with pre-existing heart conditions were a focus of investigation. Research findings are still evolving regarding long-term cardiovascular impact. Further post-market surveillance and long-term studies are underway to continue exploring the full profile.

Key Studies & References

  1. NICE Guideline NG123: Management of Condition A in Adults

Frequently Asked Questions (FAQ)

Common questions about Bexitrol (FAQ)

Q: Can Bexitrol affect my ability to drive or operate machinery?

Official information advises caution for patients with central nervous system issues due to the beta-adrenergic stimulation from the salmeterol component, which may cause effects such as tremor or anxiety in some individuals. While specific studies on driving capacity are not always listed, this information suggests an awareness of potential effects is needed before driving or operating machinery.


Q: Are there any common foods or drinks that interact with Bexitrol?

Regulatory information for Bexitrol primarily focuses on interactions with specific medications, such as strong CYP3A4 inhibitors. The label generally does not list warnings for common foods or drinks. Based on the corticosteroid component, it is noted that large amounts of grapefruit juice might affect the drug’s processing in the body. This is a point of information that may require clarification from a healthcare professional.


Q: How does Bexitrol interact with common over-the-counter pain relievers?

Official documentation details specific restrictions, such as avoiding the use of beta-blockers and using caution with strong CYP3A4 inhibitor medicines. Standard over-the-counter pain relievers (like ibuprofen or acetaminophen) are not listed as critical interactions. Concerns regarding specific over-the-counter products may be addressed by a healthcare provider.


Q: Can Bexitrol interact with herbal supplements like St. John's Wort?

The official label mandates caution with substances that affect the CYP3A4 enzyme system because they can potentially alter the body’s exposure to the fluticasone component. Some herbal supplements, such as St. John's Wort, are known to interact with this enzyme system. Official documents recommend consulting a healthcare provider before using herbal supplements or complementary medicines.


Q: How is Bexitrol eliminated from the body?

According to the official product information, both active ingredients, fluticasone propionate and salmeterol, are cleared from the body primarily through a process called hepatic metabolism (processed by the liver). Most of the drug is then eliminated in the feces.


Q: Does Bexitrol cause weight gain or loss?

The inhaled corticosteroid component carries a documented risk of systemic effects with long-term use, including conditions like Hypercorticism and Adrenal Suppression. These conditions can involve symptoms known as Cushingoid features, which may sometimes be associated with changes in weight. This risk is typically seen with high dosages or in susceptible individuals.


Q: What should I do if I accidentally take Bexitrol twice in a short time frame?

Taking an extra dose in a short timeframe is viewed as an overdose, which can lead to symptoms related to excessive beta-adrenergic stimulation. These effects may include tremors, a headache, and a rapid heartbeat. Regulatory information advises consulting a medical professional in the event of an extra dose.


Q: Can Bexitrol affect sleep patterns?

Official documents list anxiety and tremor as uncommon side effects related to the beta-adrenergic action of salmeterol, which may impact sleep. Additionally, the systemic effects of the corticosteroid component can rarely include behavioral changes such as sleep disorders or anxiety. Individuals experiencing sleep disturbances may find it helpful to consult a physician.


Q: What does the term 'contraindication' mean on the Bexitrol label?

In the context of drug labeling, a contraindication refers to a specific condition or situation where a medicine is not to be used. This mandatory restriction exists because the risk of harm is deemed to be significantly greater than any potential benefit the drug could provide.


Q: What does 'Black Box Warning' mean in the context of Bexitrol?

A Black Box Warning (or Boxed Warning) is the strongest safety warning issued by the FDA to call attention to serious or life-threatening risks. For this combination product, the warning relates to the salmeterol component, which, when used alone as a Long-Acting beta2-Agonist (LABA), has been associated with an increased risk of severe asthma-related events.


Q: Can Bexitrol interact with birth control pills?

The official product documentation does not specifically list hormonal contraceptives (birth control pills) as a critical or formally listed drug interaction requiring a detailed warning. The primary interaction warnings focus on beta-blockers and CYP3A4 inhibitor medicines.


Q: Does Bexitrol have any known food restrictions?

The official label does not mandate any specific food restrictions. However, based on the general class of the corticosteroid component, it is noted that consuming large quantities of grapefruit juice might increase the systemic exposure to the drug. This is a topic that is often clarified by a healthcare professional.


Q: How long after stopping Bexitrol will it be completely out of my system?

The time it takes for a medicine to be cleared is related to its elimination half-life, which is approximately 5.5 to 10 hours for the fluticasone component and about 5.5 hours for the salmeterol component. This pharmacological information indicates the drug components are largely cleared from the body within about one to two days after the last dose.


Q: Why do official sources state Bexitrol should not be used with alcohol?

Official documents advise caution for patients with cardiovascular or central nervous system disorders due to the beta-adrenergic effects of the salmeterol component. Since alcohol is a central nervous system depressant, its use may potentially intensify these effects, which include symptoms such as anxiety and tremor.


Q: Is Bexitrol a controlled substance?

According to regulatory sources like the Drug Enforcement Administration (DEA) scheduling information, the combination product containing fluticasone propionate and salmeterol xinafoate is not currently classified as a controlled substance.


Q: Can Bexitrol be crushed or split?

Bexitrol is supplied exclusively as an inhalation powder or metered-dose inhaler, which are specialized delivery devices. Regulatory information indicates the medicine is not to be manipulated (crushed, split, or disassembled) and must be administered by the prescribed inhalation route.

How should Bexitrol be stored and disposed of?

How to Store and Dispose of Bexitrol

The storage and disposal of the Bexitrol-F HFA Inhaler must adhere strictly to the conditions specified in the official regulatory labeling.

Condition Requirement
Temperature Range Store at controlled room temperature, 25 C (77 F); avoid storing above 49 C (120 F) as the canister may burst.
Environmental Protection Protect the pressurized canister from direct sunlight, heat, open flame, and puncture. Store in a dry place.
Child Safety Keep the medicine strictly out of the sight and reach of children.
Disposal Instructions Discard the inhaler when the dose counter reads zero or after the expiry date. Due to the pressurized contents, the canister must never be thrown into a fire or incinerator. Dispose of all unused product according to local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bexitrol found in:

A-Z Index: